Skip to main content
. 2016 Sep 18;2016(9):CD006992. doi: 10.1002/14651858.CD006992.pub2

Ning 2014.

Methods Multicentre, double‐blind, placebo‐controlled trial
Participants Participants with type 2 diabetes inadequately controlled (HbA1c 7.5%‐11.0%) on stable therapy with long‐acting, intermediate‐acting or premixed insulin, with or without concomitant metformin
Interventions Vildagliptin 50 mg twice a day (n = 146) or placebo (n = 147)
Outcomes HbA1c, fasting blood glucose, BMI
Notes Need to determine if subgroup analysis with insulin monotherapy is possible